Raloxifene

Raloxifene: An Overview

Chemical structure of Raloxifene.

Raloxifene is a drug that belongs to a class of medications known as selective estrogen receptor modulators (SERMs). It is primarily used in the prevention of osteoporosis in postmenopausal women, but its potential applications in cancer prevention are also under investigation.

Raloxifene and Osteoporosis Prevention

Healthy bone (left) vs. Osteoporotic bone (right)

Osteoporosis is a condition characterized by weakened bones that are prone to fracture. Postmenopausal women are at a heightened risk due to the natural decline in estrogen levels, which is instrumental in maintaining bone density.

Raloxifene's estrogenic effects on bone tissue help:

• Increase bone mineral density
• Reduce the rate of bone turnover
• Lower the risk of spinal fractures in postmenopausal women with osteoporosis

Raloxifene in Cancer Prevention

Studies have indicated that Raloxifene might reduce the risk of hormone receptor-positive breast cancer in postmenopausal women. Its ability to block estrogen's effects on breast tissue is the basis for this potential benefit. However, further research is ongoing to fully understand the scope and limitations of Raloxifene as a cancer-prevention drug.

Side Effects and Considerations

Like all medications, Raloxifene has its set of potential side effects:

• Hot flashes
• Leg cramps
• Increased risk of blood clots
• Possible increased risk of stroke

Patients are encouraged to discuss with their healthcare provider about the potential risks and benefits before starting Raloxifene therapy.

Conclusion

Raloxifene, as a SERM, offers significant benefits in the realm of osteoporosis prevention. Its potential role in cancer prevention is promising, but more research is needed. As with any drug, understanding its effects, both positive and negative, is essential for making informed healthcare decisions.

Pharmacological Classification: Selective Estrogen Receptor Modulators (SERMs)

SERMs are a distinctive class of compounds that exert their effects by binding to estrogen receptors. Depending on the tissue, they can act either as estrogen agonists (mimicking estrogen) or antagonists (blocking estrogen).

How SERMs Work

• Agonistic Action: In certain tissues, like bones, SERMs mimic the positive effects of estrogen, which can help in the prevention of bone loss.
• Antagonistic Action: In other tissues, such as the breast, SERMs can block the effects of estrogen, potentially reducing the risk of certain types of breast cancer.

Raloxifene (ral ox' i feen) is a selective estrogen receptor modulator that has estrogen-like effects (agonism) on bone and the cardiovascular system but antiestrogen activity (antagonism) on breast and uterus tissue.  This differential activity takes advantage of the beneficial effects of estrogens on bone in decreasing bone resorption and turnover and thus preventing osteoporosis, while avoiding the potential harmful effects of estrogen stimulation of breast and uterine tissue. 

Mechanism of action of Raloxifene

In several large clinical trials, raloxifene was shown to increase bone mineral density and prevent bone fractures in postmenopausal women at high risk for osteoporosis, while decreasing serum cholesterol levels (both total and LDL) and without stimulating breast and uterine growth. 

FDA approval information for Raloxifene

Raloxifene was approved for treatment and prevention of postmenopausal osteoporosis in the United States in 1997, and indications were expanded in 2007 to include reduction of risk of breast cancer in postmenopausal women with osteoporosis as well as those at high risk of breast cancer.  Raloxifene is available in tablets of 60 mg generically and under the brand name Evista, and the recommended dose is 60 mg daily. 

Side effects of Raloxifene

side effects are not common, but can include hot flashes, leg cramps, peripheral edema, arthralgias and sweating.  Rare, but potentially severe adverse events include deep venous thrombosis, pulmonary embolism and ischemic strokes, side effects that it shares with estrogen. 

Obstetrical and Gynecological Agents

• Emergency contraceptive agents
  • Levonorgestrel, Ulipristal

• Estrogens and Oral contraceptives

• • Selective estrogen receptor modulators
    • Bazedoxifene, Ospemifene, Raloxifene
  • Infertility agents

• Antiestrogens
  • Clomiphene, Letrozole, Tamoxifen

• Gonadotropins
  • Chorionic gonadotropin, Follicle stimulating hormone, Luteinizing hormone, Human gonadotropin releasing hormone

• Pregnancy termination agents
  • Mifepristone
• Progesterone and the Progestins

• Dailymed label info on Raloxifene
• FDA Raloxifene

Raloxifene Resources
Latest articles Most recent articles Ongoing trials	Wikipedia

Raloxifene Resources
Latest articles Most recent articles Ongoing trials	Wikipedia